GENARS238 Germany AMR n/a Organism Susceptibility E. coli n/a (within the labs testing of E. cloacae framework of labs in project in university isolates against P. mirabilis publications DART [German 6 university hospitals 25 antibiotic P. aeruginosa Antibiotic hospitals) classes S. aureus Resistance strategy]) BulSTAR76 Bulgaria AMR Public Organism Hospitals Isolation and All clinically n/a (28 public, funding susceptibility significant reported 45 hospital and (Bulgarian testing as WHO and 6 antibiotic Ministry of isolated DDD/100 private Health) from blood, bed days; cerebrospinal website, fluid, upper and lower respiratory publications tract, urine and wound samples AURES77 Austria AMR Publicly Hospitals Susceptibility S. pyogenes n/a Public (contributes funded and primary testing of S. reports; data to and (Federal care sector isolates from pneumoniae [ECDC]) antibiotic Ministry of (reported blood cultures H. influenzae Health, separately) and E. coli publications Family and cerebrospinal P. mirabilis Youth) fluid S. aureus NORM61, 239 Norway AMR n/a n/a n/a n/a n/a n/a Annual (contributes resistance public data to reports, [ECDC]) publications
GENARS238 (within the framework of DART [German Antibiotic Resistance strategy]) Germany labs in 6 university hospitals) AMR project n/a Organism labs in university hospitals Susceptibility testing of isolates against 25 antibiotic classes E. coli E. cloacae P. mirabilis P. aeruginosa S. aureus n/a publications BulSTAR76 Bulgaria (28 public, 45 hospital and 6 private AMR and antibiotic Public funding (Bulgarian Ministry of Health) Organism Hospitals Isolation and susceptibility testing All clinically significant isolated from blood, cerebrospinal fluid, upper and lower respiratory tract, urine and wound samples n/a reported as WHO DDD/100 bed days; website, publications AURES77 (contributes data to [ECDC]) Austria AMR and antibiotic Publicly funded (Federal Ministry of Health, Family and Youth) Hospitals and primary care sector (reported separately) Susceptibility testing of isolates from blood cultures and cerebrospinal fluid S. pyogenes S. pneumoniae H. influenzae E. coli P. mirabilis S. aureus n/a Public reports; publications NORM61, 239 (contributes data to [ECDC]) Norway AMR resistance n/a n/a n/a n/a n/a n/a Annual public reports, publications
National-surveillance-and-reporting-of-antimicrobial-resistance-and-antibiotic-usage-for-human-health-in-Australia.docx